Clinical Trials Directory

Trials / Completed

CompletedNCT06976359

Association of C-reactive Protein-albumin-lymphocyte Index (CALLY) With All-cause Mortality in Diabetic Patients

The National Health and Nutrition Examination Survey

Status
Completed
Phase
Study type
Observational
Enrollment
3,988 (actual)
Sponsor
Kunming Children's Hospital · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Accepted

Summary

Based on retrospective cohort data from 3,988 diabetic patients in the NHANES database, this study is the first to show a significant negative correlation between the CALLY index and all-cause mortality in diabetic patients, with good predictive ability for their survival risk. Our findings can help clinicians better assess disease progression in diabetic patients and provide a reference for personalized, precision medicine.

Detailed description

All analyses accounted for NHANES sample weights, clustering, and stratification. We used EmpowerStats (v4.1, www.empowerstats.com) and R software (v4.4.1, www.r-project.org). Continuous variables were expressed as weighted mean ± standard error (SE), and categorical variables as weighted percentages. Associations between the CALLY index and all-cause mortality were assessed using Cox proportional hazards models. Model 1 was the unadjusted crude model. Model 2 included adjustments for age, sex, race, BMI, PIR, education, smoking, and alcohol consumption. Model 3 was the fully adjusted model including additional covariates, HDL, TC, BUN, uric acid, SCR, physical activity, energy intake, hypertension, CVD. Kaplan-Meier survival curves were used to compare survival across CALLY quartiles; differences were assessed using log-rank tests. Nonlinear associations were examined with smoothed curve fitting. Subgroup analyses explored consistency across strata. ROC curves and AUC were used to compare the predictive performance of CALLY, SII, PLR, and NLR. P \< 0.05 was considered statistically significant.

Conditions

Timeline

Start date
2025-04-08
Primary completion
2025-05-08
Completion
2025-05-08
First posted
2025-05-16
Last updated
2025-05-16

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06976359. Inclusion in this directory is not an endorsement.